Steroids harmed community-acquired pneumonia patients? (REMAP-CAP)
Results contradict the new steroids-for-most critical care paradigm
In 2024, the leading U.S. critical care society advised that most patients with critical illness—including severe community-acquired pneumonia (CAP), septic shock, and acute respiratory distress syndrome (ARDS)—should receive corticosteroids.
SCCM Guideline Update: Steroids for Community-Acquired Pneumonia, ARDS, Septic Shock
Steroids are good medicine in the ICU, U.S. critical care professional societies agree.
2023 ATS vs ESICM Guidelines for ARDS: How They Differ
Note: PulmCCM has no affiliation with ATS, ESICM, SCCM or any other professional society.
This was based on what seemed to be an abundance of evidence, some of the most convincing of which was the CAPE COD trial. Among 800 patients at 31 French ICUs with severe pneumonia (excluding septic shock and influenza patients), those randomized to receive adjunctive hydrocortisone had a dramatic ~50% relative reduction in mortality, and a ~6% absolute reduction in mortality.
Corticosteroids for community-acquired pneumonia (CAPE COD trial)
Corticosteroids for community-acquired pneumonia have been studied with inconclusive results, and expert guidelines currently advise against their use except in patients with refractory septic shock. Only a few trials have tested the utility of steroids for pneumonia in ICU patients; one of the largest and most recent ones enrolling 586 patients at U.S.…
REMAP-CAP Throws a Curve
REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-Acquired Pneumonia) is a randomized trial “platform”, i.e., a framework to continuously enroll subjects with pneumonia and test various questions, without the need to design a new trial for each new question.
REMAP-CAP enrolls patients at hundreds of sites in ~25 countries, mostly in Europe. Its Bayseian “adaptive” design directs enrollment dynamically in a pseudo-randomized fashion, and its data are analyzed and reported as posterior probabilities rather than in the confidence intervals and p-values of conventional frequentist trials.
In 2020, REMAP-CAP added to the signal that steroids (hydrocortisone) appeared to be beneficial in patients with severe Covid pneumonia. Dexamethasone soon became standard therapy for severe Covid, based on the frequentist RECOVERY trial.
The REMAP-CAP platform continued to “randomize” community-acquired pneumonia patients without Covid to hydrocortisone (50 mg I.V. every 6 hours for 7 days) through 2023.
(We’ll put scare quotes around “randomize” as the platform does not follow the familiar conventions of frequentist trials, often allocating patients to arms unequally and in variable ratios according to its own internal mathematical logic.)
Did Steroids Harm Severe CAP Patients?
Keep reading with a 7-day free trial
Subscribe to PulmCCM to keep reading this post and get 7 days of free access to the full post archives.